Seminars in Cancer Biology

Papers
(The TQCC of Seminars in Cancer Biology is 58. The table below lists those papers that are above that threshold based on CrossRef citation counts. The publications cover those that have been published in the past four years, i.e., from 2019-03-01 to 2023-03-01.)
ArticleCitations
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside386
Ferroptosis is a type of autophagy-dependent cell death316
Akt in cancer: Mediator and more235
Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance228
CircRNAs and cancer: Biomarkers and master regulators213
mTOR: Role in cancer, metastasis and drug resistance184
Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition179
Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy161
CRISPR/Cas9 for cancer research and therapy151
Mechanisms of PTEN loss in cancer: It’s all about diversity127
Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment124
P21 activated kinase signaling in cancer111
Matrix Metalloproteinases: A challenging paradigm of cancer management109
Emerging roles of ECM remodeling processes in cancer104
Oxidative stress-modulating drugs have preferential anticancer effects - involving the regulation of apoptosis, DNA damage, endoplasmic reticulum stress, autophagy, metabolism, and migration101
PIK3CA in cancer: The past 30 years91
RAS-mediated oncogenic signaling pathways in human malignancies88
Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities85
AGC kinases, mechanisms of regulation ‎and innovative drug development83
Ras and Rap1: A tale of two GTPases83
Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma81
Emerging role of PI3K/AKT in tumor-related epigenetic regulation79
Flavonoids nanoparticles in cancer: Treatment, prevention and clinical prospects77
MAPK signalling pathway in cancers: Olive products as cancer preventive and therapeutic agents77
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond72
Connections between metabolism and epigenetics in cancers70
The roles of sirtuins family in cell metabolism during tumor development70
Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights69
The circulating transcriptome as a source of cancer liquid biopsy biomarkers69
Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer63
Laminin 332 in cancer: When the extracellular matrix turns signals from cell anchorage to cell movement61
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy61
RAS mutations in human cancers: Roles in precision medicine60
Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells59
Clinical applications of gut microbiota in cancer biology59
The multiverse nature of epithelial to mesenchymal transition58
0.0092260837554932